Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Guardant Health, Inc.    GH

GUARDANT HEALTH, INC.

(GH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Guardant Health : Announces Webcast of Third Quarter Financial Results on November 5, 2020

10/16/2020 | 04:07pm EST

Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2020 after market close on Thursday, November 5, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

Source: Guardant Health, Inc.


© Business Wire 2020
All news about GUARDANT HEALTH, INC.
11/20GUARDANT HEALTH, INC. : Entry into a Material Definitive Agreement, Creation of ..
AQ
11/17GUARDANT HEALTH, INC. : Other Events, Financial Statements and Exhibits (form 8-..
AQ
11/16GUARDANT HEALTH, INC. : Prices $1 Billion Convertible Senior Notes Offering
BU
11/16GUARDANT HEALTH, INC. : Announces Proposed Convertible Senior Notes Offering
BU
11/05GUARDANT HEALTH : Management's Discussion and Analysis of Financial Condition an..
AQ
11/05GUARDANT HEALTH, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
11/05GUARDANT HEALTH : 3Q Earnings Snapshot
AQ
11/05GUARDANT HEALTH : Reports Third Quarter 2020 Financial Results
BU
10/16GUARDANT HEALTH : Announces Webcast of Third Quarter Financial Results on Novemb..
BU
10/15GUARDANT HEALTH : Announces Closing of Public Offering of Common Stock, Includin..
BU
More news
Financials (USD)
Sales 2020 285 M - -
Net income 2020 -209 M - -
Net cash 2020 1 305 M - -
P/E ratio 2020 -57,4x
Yield 2020 -
Capitalization 12 109 M 12 109 M -
EV / Sales 2020 37,9x
EV / Sales 2021 29,2x
Nbr of Employees 622
Free-Float 92,3%
Chart GUARDANT HEALTH, INC.
Duration : Period :
Guardant Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GUARDANT HEALTH, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 130,78 $
Last Close Price 121,12 $
Spread / Highest target 19,7%
Spread / Average Target 7,97%
Spread / Lowest Target -0,92%
EPS Revisions
Managers
NameTitle
Helmy Eltoukhy Chief Executive Officer & Director
AmrAli H. Talasaz Chairman, President & Chief Operations Officer
Derek A. Bertocci Chief Financial Officer
Kumud Kalia Chief Information Officer
Darya Chudova Senior Vice President-Technology
Sector and Competitors
1st jan.Capitalization (M$)
GUARDANT HEALTH, INC.55.00%11 863
EXACT SCIENCES CORPORATION27.80%18 796
INVITAE CORPORATION210.35%8 846
ADAPTIVE BIOTECHNOLOGIES CORPORATION57.09%6 428
IOVANCE BIOTHERAPEUTICS, INC.42.27%5 777
SEEGENE INC--.--%4 507